During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Explore the benefits of supportive care in large B-cell lymphoma treatment. Learn how it can ease symptoms, boost quality of life, and more.

Having a well-rounded care team can make large B-cell lymphoma treatment easier. Learn how nurses, social workers, and other ...

Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Incyte (INCY) stock and Xencor (XNCR) stock are in focus as jointly developed antibody drug tafasitamab succeeds in a ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

Incyte said on Monday its experimental combo therapy helped patients live longer without their disease worsening in a late-stage study ‍of a type of blood cancer, sending its shares up about 3% in ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Among patients treated in the first-line setting, the overall response rate was 57.1%, compared with 38.1% in those treated in the second line or later.

In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...